Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 11.00
+1.00 (10.00%)
Apr 30, 2026, 12:59 PM CET
Xbrane Biopharma AB Market Cap
Xbrane Biopharma AB has a market cap or net worth of 226.66 million as of April 30, 2026. Its market cap has decreased by -19.16% in one year.
Market Cap
226.66M
Enterprise Value
198.38M
Revenue
152.35M
Ranking
n/a
PE Ratio
1.78
Stock Price
11.00
Market Cap Chart
Since February 3, 2016, Xbrane Biopharma AB's market cap has increased from 131.05M to 226.66M, an increase of 72.95%. That is a compound annual growth rate of 5.50%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 29, 2026 | 206.05M | -1.96% |
| Dec 30, 2025 | 210.17M | -14.54% |
| Dec 30, 2024 | 245.94M | -17.28% |
| Dec 29, 2023 | 297.31M | -86.83% |
| Dec 30, 2022 | 2.26B | -13.94% |
| Dec 30, 2021 | 2.62B | 58.03% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Bio-Works Technologies AB | 314.18M |
| Mendus AB | 311.04M |
| Xintela AB | 228.24M |
| Isofol Medical AB | 225.63M |
| Initiator Pharma | 214.26M |
| Active Biotech AB | 175.30M |
| AlzeCure Pharma AB | 160.31M |
| Diamyd Medical AB | 158.08M |